

DAFTAR PUSTAKA

- Aiguabella, M., Falip, M., Villanueva, V., De La Peña, P., Molins, A., Garcia-Morales, I., dkk., 2011. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: A multicentric observational study. *Seizure*, **20**: 60–64.
- Aleyadeh, R. dan Carson, R.P., 2025. Fosphenytoin, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Allredge, B.K., Gelb, A.M., Isaacs, S.M., Corry, M.D., Allen, F., Ulrich, S., dkk., 2001. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. *The New England Journal of Medicine*, **345**: 631–637.
- Almadani, O., Alroba, R., Alfakhri, A., Almohareb, S., Althunian, T., dan Alrwisan, A.A., 2024. Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study. *Drugs - Real World Outcomes*, **11**: 331–339.
- Appleton, R.E., Rainford, N.E.A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., dkk., 2020. Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: The eclipse rct. *Health Technology Assessment*, **24**: 1–96.
- Barcia Aguilar, C., Sánchez Fernández, I., dan Loddenkemper, T., 2020. Status Epilepticus-Work-Up and Management in Children. *Seminars in Neurology*, **40**: 661–674.
- Baulac, M., Brodie, M.J., Elger, C.E., Krakow, K., Stockis, A., Meyvisch, P., dkk., 2007. Levetiracetam Intravenous Infusion as an Alternative to Oral Dosing in Patients with Partial-Onset Seizures. *Epilepsia*, **48**: 589–592.
- Beach, E.C. dan De Jesus, O., 2026. Ileus, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Bereda, G., 2021. Classifying Causality of an Adverse Drug Reaction: Naranjo Algorithm. *International Journal of Pharmacy and Chemistry*, **7**: 125–127.
- Berning, S., Boesebeck, F., van Baalen, A., dan Kellinghaus, C., 2009. Intravenous levetiracetam as treatment for status epilepticus. *Journal of Neurology*, **256**: 1634–1642.
- Betjemann, J.P. dan Lowenstein, D.H., 2015. Status epilepticus in adults. *The Lancet Neurology*, **14**: 615–624.
- Bounds, C.G. dan Patel, P., 2025. Benzodiazepines, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

- BPOM dan JICA, 2020. Modul Farmakovigilans bagi Tenaga Kesehatan Profesional.
- Brophy, G.M., Bell, R., Claassen, J., Alldredge, B., Bleck, T.P., Glauser, T., dkk., 2012. Guidelines for the Evaluation and Management of Status Epilepticus. *Neurocritical Care*, **17**: 3–23.
- Burman, R.J., Raimondo, J.V., Jefferys, J.G.R., Sen, A., dan Akerman, C.J., 2020. The transition to status epilepticus: how the brain meets the demands of perpetual seizure activity. *Seizure*, **75**: 137–144.
- Chamberlain, J.M., Kapur, J., Shinnar, S., dan Elm, J., 2019. Efficacy of Levetiracetam, Foephentoin, and Valproate for Established Status Epilepticus By Age Group. *Physiology & behavior*, **176**: 139–148.
- Chen, J.W.Y., Naylor, D.E., dan Wasterlain, C.G., 2007. Advances in the pathophysiology of status epilepticus. *Acta Neurologica Scandinavica. Supplementum*, **186**: 7–15.
- Chen, J.W.Y. dan Wasterlain, C.G., 2006. Status epilepticus: pathophysiology and management in adults. *The Lancet. Neurology*, **5**: 246–256.
- Chiewthanakul, P., Noppaklao, P., Sawanyawisuth, K., dan Tiamkao, S., 2015. Hyperglycemia associated with seizure control in status epilepticus. *Epilepsy & Behavior*, **49**: 155–157.
- Coplin, W.M., Rhoney, D.H., Rebeck, J.A., Clements, E.A., Cochran, M.S., dan O’Neil, B.J., 2002. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. *Neurological Research*, **24**: 842–848.
- Dell’Aquila, J. dan Soti, V., 2021. Treating Status Epilepticus: Phenytoin Versus Levetiracetam. *Cureus*, **13**: 1–9.
- DeLorenzo, R.J., Hauser, W.A., Towne, A.R., Boggs, J.G., Pellock, J.M., Penberthy, L., dkk., 1996. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. *Neurology*, **46**: 1029–1035.
- DeLorenzo, R.J., Waterhouse, E.J., Towne, A.R., Boggs, J.G., Ko, D., DeLorenzo, G.A., dkk., 1998. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. *Epilepsia*, **39**: 833–840.
- DeMott, J.M., Slocum, G.W., Gottlieb, M., dan Peksa, G.D., 2020. Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. *Epilepsy & Behavior*, **111**: 107286.

- Deng, B., Dai, Y., Wang, Q., Yang, J., Chen, X., Liu, T., dkk., 2022. The clinical analysis of new-onset status epilepticus. *Epilepsia Open*, **7**: 771–780.
- DeToledo, J.C. dan Ramsay, R.E., 2000. Fosphenytoin and Phenytoin in Patients with Status Epilepticus. *Drug Safety*, **22**: 459–466.
- Dham, B.S., Hunter, K., dan Rincon, F., 2014. The epidemiology of status epilepticus in the United States. *Neurocritical Care*, **20**: 476–483.
- Dube, S.K. dan Rath, G.P., 2012. Cough and bronchospasm after rapid intravenous administration of phenytoin. *Journal of Neurosurgical Anesthesiology*, **24**: 239–240.
- Dubey, D., Kalita, J., dan Misra, U.K., 2017. Status epilepticus: Refractory and super-refractory. *Neurology India*, **65**: S12–S17.
- Elshater, A.A., Sadek, A.A., dan Abdelkreem, E., 2023. Levetiracetam and Midazolam vs Midazolam Alone for First-Line Treatment of Children With Generalized Convulsive Status Epilepticus (Lev-Mid Study): A Randomized Controlled Trial. *Indian Pediatrics*, **60**: 630–636.
- F, Y., C, D., dan N, G., 2022. Prognostic scores in status epilepticus: A systematic review and meta-analysis. *Epilepsia*, **64**: 17–28.
- Falip, M., Carreño, M., Amaro, S., Donaire, A., Delgado, R., Toledo, M., dkk., 2006. Use of levetiracetam in hospitalized patients. *Epilepsia*, **47**: 2186–2188.
- Gasti, D.R., Hapsari, A.S., dan Ulifah, K.I., 2023. Comparison efficacy and safety sodium valproate versus combination sodium valproate and levetiracetam for treatment epilepsy in children: a meta-analysis. *Pediatric Sciences Journal*, **4**: 54–59.
- Gettings, J.V., Mohammad Alizadeh Chaffjiri, F., Patel, A.A., Shorvon, S., Goodkin, H.P., dan Loddenkemper, T., 2025. Diagnosis and management of status epilepticus: improving the status quo. *The Lancet Neurology*, **24**: 65–76.
- Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., dkk., 2016. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. *Epilepsy Currents*, **16**: 48–61.
- Gupta, M. dan Tripp, J., 2025. Phenytoin, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Guterman, E.L., Betjemann, J.P., Aimetti, A., Li, J.W., Wang, Z., Yin, D., dkk., 2021. Association Between Treatment Progression, Disease Refractoriness,

and Burden of Illness Among Hospitalized Patients With Status Epilepticus. *JAMA Neurology*, **78**: 588–595.

Harsono, 2021. *Epilepsi*, 3rd ed. Gadjah Mada University Press, D.I. Yogyakarta.

Hegazy, Y., Axley, P., Lee, G., dan Gray, M., 2023. Levetiracetam Liver Injury: A Benign Antiepileptic Agent? *ACG Case Reports Journal*, **10**: e01003.

Hesdorffer, D.C., Logroscino, G., Cascino, G., Annegers, J.F., dan Hauser, W.A., 1998. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. *Neurology*, **50**: 735–741.

Holtkamp, M., Othman, J., Buchheim, K., dan Meierkord, H., 2005. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. *Journal of Neurology, Neurosurgery, and Psychiatry*, **76**: 534–539.

Hosseini, M.S. dan Namazi, S., 2023. Immediate hypersensitivity reaction to levetiracetam: a case report study. *DARU Journal of Pharmaceutical Sciences*, **32**: 435–438.

Jain, P., Aneja, S., Cunningham, J., Arya, R., dan Sharma, S., 2022. Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses. *Seizure: European Journal of Epilepsy*, **102**: 74–82.

Jobst, B.C., Ben-Menachem, E., Chapman, K.E., Fu, A., Goldman, A., Hirsch, L.J., dkk., 2019. Highlights From the Annual Meeting of the American Epilepsy Society 2018. *Epilepsy Currents*, **19**: 152–158.

Joshi, S., Rajasekaran, K., Hawk, K.M., Chester, S.J., dan Goodkin, H.P., 2018. Status epilepticus: Role for etiology in determining response to benzodiazepines. *Annals of Neurology*, **83**: 830–841.

Kadri, A., Hamud, A., Abdelgadir, I., dan Powell, C., 2021. Pediatric convulsive status epilepticus: Is levetiracetam another arrow in the quiver? *Archives of Nursing and Healthcare*, **1**: 8–11.

Kapur, J., 1999. Status epilepticus in epileptogenesis. *Current Opinion in Neurology*, **12**: 191–195.

Kapur, J., Elm, J., Chamberlain, J.M., Barsan, W., Cloyd, J., Lowenstein, D., dkk., 2019. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. *New England Journal of Medicine*, **381**: 2103–2113.

Kartek, M., Kannan, A., Anand, V., dan Sahoo, M.R., 2024. Intravenous levetiracetam versus intravenous phenytoin as second Line treatment in pediatric convulsive status epilepticus- open label randomized controlled trial 3368–3373.

- Kellinghaus, C., Rossetti, A.O., Trinka, E., Lang, N., May, T.W., Unterberger, I., dkk., 2019. Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE). *Annals of Neurology*, **85**: 421–432.
- Kim, D., Kim, J.-M., Cho, Y.W., Yang, K.I., Kim, D.W., Lee, S.-T., dkk., 2021. Antiepileptic Drug Therapy for Status Epilepticus. *Journal of Clinical Neurology (Seoul, Korea)*, **17**: 11–19.
- Knake, S., Gruener, J., Hattemer, K., Klein, K.M., Bauer, S., Oertel, W.H., dkk., 2008. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. *Journal of Neurology, Neurosurgery, and Psychiatry*, **79**: 588–589.
- Krishnan, V., Ujjanappa, V., Vegda, H., Annayappa, M.K., Wali, P., Fattepur, S., dkk., 2024. Articles Sequential levetiracetam and phenytoin in electroencephalographic neonatal seizures unresponsive to phenobarbital: a multicenter prospective observational study in India. *The Lancet Regional Health - Southeast Asia*, **25**: 100371.
- Kumar, A., Maini, K., dan Kadian, R., 2025. Levetiracetam, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Kurniawan, M., Ganiem, A.R., dan Wiratman, W., 2023. Pedoman Praktik Klinis Neurologi 2023.
- Lang, N., Esser, W., Evers, S., Kellinghaus, C., Nguento, A., Schlegel, U., dkk., 2015. Intravenous levetiracetam in clinical practice – Results from an independent registry. *Seizure*, **29**: 109–113.
- Lee, S.K., 2020. Diagnosis and Treatment of Status Epilepticus. *Journal of Epilepsy Research*, **10**: 45–54.
- Leitinger, M., Trinka, E., Gardella, E., Rohrer, A., Kalss, G., Qerama, E., dkk., 2016. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. *The Lancet. Neurology*, **15**: 1054–1062.
- Leitinger, M., Trinka, E., Giovannini, G., Zimmermann, G., Florea, C., Rohrer, A., dkk., 2019. Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. *Epilepsia*, **60**: 53–62.
- Leppik, I.E., 2018. Status epilepticus in the elderly. *Epilepsia*, **59 Suppl 2**: 140–143.
- Li, L., Zhang, Y., Jia, L., Jia, D., Faramand, A., Chong, W., dkk., 2020. Levetiracetam versus phenytoin for the treatment of established status

epilepticus: A systematic review and meta-analysis of randomized controlled trials. *Seizure*, **78**: 43–48.

Licchetta, L., Ferri, L., Morsillo, F., Faustini-Fustini, M., Toni, F., Pondrelli, F., dkk., 2023. Clinical characterization of non-ketotic hyperglycemia-related seizures: A systematic review and individual participant data meta-analysis. *Seizure: European Journal of Epilepsy*, **106**: 50–57.

Lie, I.A., Hoggen, I., Samsonsen, C., dan Brodtkorb, E., 2015. Treatment non-adherence as a trigger for status epilepticus: An observational, retrospective study based on therapeutic drug monitoring. *Epilepsy Research*, **113**: 28–33.

Lu, M., Faure, M., Bergamasco, A., Spalding, W., Benitez, A., Moride, Y., dkk., 2020a. Epidemiology of status epilepticus in the United States: A systematic review. *Epilepsy & Behavior*, **112**: 107459.

Lynch, B.A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., dkk., 2004. The synaptic vesicle is the protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proceedings of the National Academy of Sciences of the United States of America*, **101**: 9861–9866.

Lynch, M.W., Rutecki, P.A., dan Sutula, T.P., 1996. The effects of seizures on the brain. *Current Opinion in Neurology*, **9**: 97–102.

Meierkord, H., Boon, P., Engelsens, B., Göcke, K., Shorvon, S., Tinuper, P., dkk., 2010. EFNS guideline on the management of status epilepticus in adults. *European Journal of Neurology*, **17**: 348–355.

Mevius, A., Joeres, L., Gille, P., Molzan, M., Foscett, N., Wilke, T., dkk., 2023. Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database. *Brain Communications*, **5**: fcad145.

Migdady, I., Rosenthal, E.S., dan Cock, H.R., 2022. Management of status epilepticus: a narrative review. *Anaesthesia*, **77**: 78–91.

Möddel, G., Bunten, S., Dobis, C., Kovac, S., Dogan, M., Fischera, M., dkk., 2009. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. *Journal of Neurology, Neurosurgery, and Psychiatry*, **80**: 689–692.

Naeem, B., Ashfaq, M., dan Qureshi, M.A., 2023. Original Article Efficacy Of Levetiracetam Versus Phenytoin As A Second-Line Antiepileptic Drug In The Management Of Benzodiazepine-Refractory Status Epilepticus Among **35**: 410–414.

- Nakamura, K., Marushima, A., Takahashi, Y., Mochizuki, M., Kimura, A., Fukuda, Y., dkk., 2023. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial. *Journal of Neurology, Neurosurgery & Psychiatry*, **94**: 42–48.
- Nalisetty, S., Kandasamy, S., Sridharan, B., dan Vijayakumar, V., 2020. Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus.
- Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., dkk., 1981. A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology & Therapeutics*, **30**: 239–245.
- Nascimento, F.A., Takeshita, B.T., dan Kowacs, P.A., 2016. Phenytoin-induced isolated chronic, nocturnal dry cough. *Epilepsy & Behavior Case Reports*, **5**: 44–45.
- National Institute for Health and Care Excellence, 2022. Epilepsies in children, young people and adults (NG217). *Nice Guideline*, .
- Naylor, D.E., Liu, H., dan Wasterlain, C.G., 2005. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, **25**: 7724–7733.
- Nebeker, J.R., Barach, P., dan Samore, M.H., 2004. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. *Annals of Internal Medicine*, **140**: 795–801.
- Octaviana, F., Harsono, A.R., Wiratman, W., Indrawati, L.A., dan Budikayanti, A., 2025. Use of oral anti-seizure medication via nasogastric tube to treat IV-diazepam resistant status epilepticus in a setting with limited resources: An observational study. *Epilepsy Research*, **212**: 107544.
- Osias, J., McVey, P., Ayvaz, S., Frontera, J., dan McWilliams-Dunnigan, L., 2015. Predictors of Outcome in Status Epilepticus in the Neuro ICU (P7.172). *Neurology*, **84**: P7.172.
- Ozdilek, B., Midi, I., Agan, K., dan Bingol, C.A., 2013. Episodes of status epilepticus in young adults: Etiologic factors, subtypes, and outcomes. *Epilepsy & Behavior*, **27**: 351–354.
- Patel, N.C., Landan, I.R., Levin, J., Szaflarski, J., dan Wilner, A.N., 2006. The use of levetiracetam in refractory status epilepticus. *Seizure*, **15**: 137–141.

- Popławska, M., Borowicz, K.K., dan Czuczwar, S.J., 2015. The safety and efficacy of fosphenytoin for the treatment of status epilepticus. *Expert Review of Neurotherapeutics*, **15**: 983–992.
- Rahman, M., Awosika, A.O., dan Nguyen, H., 2025. Valproic Acid, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Romoli, M., Perucca, E., dan Sen, A., 2020. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. *Epilepsy & Behavior: E&B*, **103**: 106861.
- Rossetti, A.O., Logroscino, G., dan Bromfield, E.B., 2006. A clinical score for prognosis of status epilepticus in adults. *Neurology*, **66**: 1736–1738.
- Rüegg, S., Naegelin, Y., Hardmeier, M., Winkler, D.T., Marsch, S., dan Fuhr, P., 2008. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. *Epilepsy & Behavior: E&B*, **12**: 477–480.
- Sathe, A.G., Mishra, U., Ivaturi, V., Brundage, R.C., Cloyd, J.C., Elm, J.J., dkk., 2021. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. *Journal of Clinical Pharmacology*, **61**: 763–768.
- Sculier, C., Gaínza-Lein, M., Sánchez Fernández, I., dan Loddenkemper, T., 2018. Long-term outcomes of status epilepticus: A critical assessment. *Epilepsia*, **59**: 155–169.
- Shneker, B.F. dan Fountain, N.B., 2003. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. *Neurology*, **61**: 1066–1073.
- Shorvon, S. dan Sen, A., 2020. What is status epilepticus and what do we know about its epidemiology? *Seizure - European Journal of Epilepsy*, **75**: 131–136.
- Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., dkk., 2012. Intramuscular versus intravenous therapy for prehospital status epilepticus. *The New England Journal of Medicine*, **366**: 591–600.
- Sills, G.J. dan Rogawski, M.A., 2020. Mechanisms of action of currently used antiseizure drugs. *Neuropharmacology*, **168**: 107966.
- Smythe, M.A. dan Umstead, G.S., 1989. Phenytoin hepatotoxicity: a review of the literature. *DICP: the annals of pharmacotherapy*, **23**: 13–18.
- Starreveld, E. dan Starreveld, A.A., 2000. Status epilepticus. Current concepts and management. *Canadian Family Physician*, **46**: 1817–1823.

- Strzelczyk, A., Brunklaus, A., Rosenow, F., Paprocka, J., Schubert-Bast, S., dan Kämpf, L., 2024. Cost-of-illness review of status epilepticus in Europe. *Epilepsy & Behavior*, **161**: .
- Sutter, R., Kaplan, P.W., dan Rüegg, S., 2013. Outcome predictors for status epilepticus—what really counts. *Nature Reviews Neurology*, **9**: 525–534.
- Sutter, R., Semmlack, S., dan Kaplan, P.W., 2016. Nonconvulsive status epilepticus in adults - insights into the invisible. *Nature Reviews. Neurology*, **12**: 281–293.
- Swadron, S.P., Rudis, M.I., Azimian, K., Beringer, P., Fort, D., dan Orlinsky, M., 2004. A comparison of phenytoin-loading techniques in the emergency department. *Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine*, **11**: 244–252.
- Tasya, G.A., Djatmiko, N.I., Rahman, F.H.F., dan Rahmawati, V.K., 2023a. Comparative efficacy of intravenous levetiracetam and phenytoin in status epilepticus: a systematic review and meta-analysis of randomized controlled trials. *Medical Journal of Indonesia*, **32**: 45–51.
- Tasya, G.A., Djatmiko, N.I., Rahman, F.H.F., dan Rahmawati, V.K., 2023b. Comparative efficacy of intravenous levetiracetam and phenytoin in status epilepticus: a systematic review and meta-analysis of randomized controlled trials. *Medical Journal of Indonesia*, **32**: 45–51.
- Treiman, D.M., Meyers, P.D., Walton, N.Y., Collins, J.F., Colling, C., Rowan, A.J., dkk., 1998. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. *The New England Journal of Medicine*, **339**: 792–798.
- Trinka, E., 2009. What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam? *Epilepsia*, **50**: 40–43.
- Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A.O., Scheffer, I.E., Shinnar, S., dkk., 2015. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. *Epilepsia*, **56**: 1515–1523.
- Trinka, E., Höfler, J., Zerbs, A., dan Brigo, F., 2014. Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review. *CNS Drugs*, **28**: 623–639.
- Trinka, E., Rainer, L.J., Granbichler, C.A., Zimmermann, G., dan Leitinger, M., 2023. Mortality, and life expectancy in Epilepsy and Status epilepticus-current trends and future aspects. *Frontiers in Epidemiology*, **3**: 1081757.

- Tziakouri, A., Novy, J., dan Rossetti, A.O., 2025. Sex-based analysis of status epilepticus management and outcome: A cohort study. *Epilepsia*, **66**: e41–e46.
- Ungureanu, A., Rus, L.L., Gligor, F.G., Prodan, L., dan Roman-Filip, C., 2016. INTRAVENOUS LEVETIRACETAM AS SECOND LINE OPTION FOR **64**: .
- Verrotti, A., Prezioso, G., Sabatino, F.D., Franco, V., Chiarelli, F., dan Zaccara, G., 2015. The adverse event profile of levetiracetam: A meta-analysis on children and adults. *Seizure - European Journal of Epilepsy*, **31**: 49–55.
- Vignesh, V., Rameshkumar, R., dan Mahadevan, S., 2020. Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: *Indian Pediatr.*, **57**: 222–227.
- Vooturi, S., Jayalakshmi, S., Sahu, S., dan Mohandas, S., 2014. Prognosis and predictors of outcome of refractory generalized convulsive status epilepticus in adults treated in neurointensive care unit. *Clinical Neurology and Neurosurgery*, **126**: 7–10.
- Wang, S., Wu, X., Xue, T., Song, Z., Tan, X., Sun, X., dkk., 2023. Efficacy and safety of levetiracetam versus valproate in patients with established status epilepticus: A systematic review and meta-analysis. *Heliyon*, **9**: e13380.
- Wang, Y.-Q., Wen, Y., Wang, M.-M., Zhang, Y.-W., dan Fang, Z.-X., 2021. Prolactin levels as a criterion to differentiate between psychogenic non-epileptic seizures and epileptic seizures: A systematic review. *Epilepsy Research*, **169**: 106508.
- Winkel, J., Jünemann, C., Menche, M., Strehlau, S., Tsalouchidou, P.-E., Habermehl, L., dkk., 2026. Status epilepticus in male and female patients: Clinical presentation, management, and outcomes. *Seizure: European Journal of Epilepsy*, **139**: 163–169.
- Woodward, M.R., Armahizer, M.J., Wang, T.I., Badjatia, N., Johnson, E.L., dan Gilmore, E.J., 2025. Status epilepticus in older adults: A critical review. *Epilepsia*, **66**: 3118–3137.
- Yang, L., Dong, X.-Z., Cui, X.-H., Liu, J.-M., Liu, W.-N., dan Zhang, L., 2021. Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis. *Journal of Clinical Neuroscience*, **89**: 422–429.
- Yasiry, Z. dan Shorvon, S.D., 2014. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. *Seizure*, **23**: 167–174.

- Yi, Z.-M., Zhong, X.-L., Wang, M.-L., Zhang, Y., dan Zhai, S.-D., 2020. Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*, **11**: .
- Yuan, F., Yang, F., Li, W., Yang, X., Gao, Q., Bi, L., dkk., 2018. Nonconvulsive status epilepticus after convulsive status epilepticus: Clinical features, outcomes, and prognostic factors. *Epilepsy Research*, **142**: 53–57.
- Zafar, A., Shahid, R., Nazish, S., Aljaafari, D., Alkhamis, F.A., Alsalman, S., dkk., 2019. Nonadherence to Antiepileptic Medications: Still a Major Issue to be Addressed in the Management of Epilepsy. *Journal of Neurosciences in Rural Practice*, **10**: 106–112.
- Zehtabchi, S., Silbergleit, R., Chamberlain, J.M., Shinnar, S., Elm, J.J., Underwood, E., dkk., 2022. Electroencephalographic Seizures in Emergency Department Patients After Treatment for Convulsive Status Epilepticus. *Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society*, **39**: 441–445.
- Zelano, J., Möller, F., Dobesberger, J., Trinka, E., dan Kumlien, E., 2014. Infections in status epilepticus: A retrospective 5-year cohort study. *Seizure - European Journal of Epilepsy*, **23**: 603–606.